AtheroGenics, Inc.{AGIX}-nasdaq Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AtheroGenics, Inc.{AGIX}-nasdaq

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (160)	11/21/2005 8:06:40 AM
From: kenhott	Read Replies (1) of 332

They have a drug partnered with Astellas (Prograf is key product for Astellas) for transplants, AGI-1096 Phase 1 completed. Drug partnered early 04. Nothing about Phase 2. Astellas does not show AGI-1096 on their progression chart. But does show FK778 for transplantation in Phase 2, for instance. I do not expect a "complete" failure for AGI-1067. I expect the company to find a subgroup that "benefits". It depends on the story for bounce. What's on my side is price at entry which gives me the freedom to have a longer term view.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next